Skip to main content
Back to News
Mecara CEO Hiromi Kawamata has been named to the EY Entrepreneurial Winning Women Asia-Pacific Class...
General
1 min read

Mecara CEO Hiromi Kawamata has been named to the EY Entrepreneurial Winning Women Asia-Pacific Class...

The AMW Read

Provides an incremental update on a specialized player in the AI-driven healthcare/diagnostics sub-segment, noting their regulatory pursuit and government grant.
NoveltySignificance
Healthcare & Bio · Player Map

Mecara CEO Hiromi Kawamata has been named to the EY Entrepreneurial Winning Women Asia-Pacific Class of 2026, recognizing her work in AI-driven digital pupillometry that measures autonomic nervous system function in just 7 seconds. The Tokyo-based startup, founded in 2019, has secured a 700 million yen government medical innovation grant and is pursuing PMDA regulatory approval for its AiLive device, which serves hospitals and corporations across Japan. Mecara plans to expand across Asia-Pacific and enter the US market within 3-5 years, transitioning from a hardware device model to a comprehensive SaaS and data analytics platform for preventive health.

#HealthTech #AI #Japan #Pupillometry #DigitalHealth #MedTech

Read Original

How This Connects

Based on Healthcare & Bio · Player Map

  1. 1w agoVeeva launches Falcon AI agent platform for autonomous drug developmentVeeva
  2. 1w agoSubtle Medical raises $33M and appoints new CEO to scale AI imaging platformSubtle Medical
  3. 1mo agoIsomorphic Labs raises $2.1B led by Thrive Capital in largest AI drug-discovery roundIsomorphic Labs
  4. 1mo agoOpenAI model outperforms doctors in ER diagnoses, achieving 67% accuracy vs 55%OpenAI
  5. 2mo agoMecara CEO Hiromi Kawamata has been named to the EY Entrepreneurial Winning Women Asia-Pacific Class... · THIS ARTICLE

Related News

Discover AI Startups

Explore 2,000+ AI companies with VC-grade analysis, funding data, and investment insights.

Explore Dashboard